Last reviewed · How we verify
MSCTC-0010
At a glance
| Generic name | MSCTC-0010 |
|---|---|
| Sponsor | IMAC Holdings, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease (PHASE1)
- Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSCTC-0010 CI brief — competitive landscape report
- MSCTC-0010 updates RSS · CI watch RSS
- IMAC Holdings, Inc. portfolio CI